Commercial Agreement Makes d-Nav Insulin Guidance Service Available to Selected Type 2 Diabetes Population in Michigan

Hygieia Announces Publication of Data in The Lancet Demonstrating Superiority of d-Nav Insulin Guidance System Plus HCP Support Over HCP Support Alone for Improving Glycemic Control

Six-month, multi-site, randomized controlled clinical study evaluated impact of d-Nav among insulin users with Type 2 diabetes —
Data will be highlighted today during ATTD 2019 parallel session —

LIVONIA, Mich., February 23, 2019 – Hygieia, a digital insulin enhancement company dedicated to making insulin therapy easier and more effective for everyone involved, announced that data demonstrating the efficacy and safety of the d-Nav® Insulin Guidance System combined with support from healthcare professionals (HCP) have been published online today in The Lancet. The data, from a multi-site, randomized, controlled clinical study conducted at three leading national diabetes centers, show that personalized, automated insulin titration provided by the d-Nav System along with dedicated HCP support generates superior glycemic control as compared to HCP support alone. Data from the study will be discussed today during a session at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019) in Berlin.

The d-Nav Insulin Guidance Service combines smart cloud-based technology and a small team of dedicated healthcare professionals to support primary care physicians and help people with diabetes achieve improved health. Using proprietary insulin-titration algorithms and patients’ individual blood glucose readings, d-Nav provides personalized insulin adjustments to enhance and simplify dosing.

Investigators also evaluated safety, particularly frequency of hypoglycemia, among the two groups.

For participants in the intervention group, average HbA1c decreased by 1.0%±1.0% compared to 0.3%±0.9% for participants in the control group. At baseline, 22.6 percent of the participants in the d-Nav (intervention) group and 31.8 percent in the control group had HbA1c <8 percent. By the end of the study, 62.4 percent of d-Nav participants achieved HbA1c <8 percent, as compared to 33.0 percent in the HCP-only group. The percent of participants who achieve HbA1c <7 percent without severe hypoglycemia was 21.5 percent in the d-Nav group and 3.4 percent in the control group. The frequency of both mild and severe hypoglycemia was similar between the two groups.

The d-Nav Insulin Guidance Service has previously demonstrated the ability to help patients attain and sustain HbA1c reductions for at least six years while generating substantial cost savings.[1],[2]

About Hygieia
Hygieia is a digital insulin enhancement company dedicated to making insulin therapy easier and more effective for everyone involved. The company is based in Livonia, Mich. and has a wholly owned subsidiary in Northern Ireland. More information is available at

# # #

Media Contact:
Michele Parisi
Forward Health Communications, Inc.
925-429-1850 (office)
925-864-5028 (cell)

[1] South Eastern Health and Care Trust (SEHCT). April 2016.

[2] Harper R, et. al. Temporary Reductions in Insulin Requirements Are Associated with Hypoglycemia in Type 2 Diabetes. Diabetes Tech & Ther. 2018